65 completed, 18 terminated, 13 active not recruiting, 11 recruiting. 123 Phase 3, 43 Phase 2.
Follow Motor Neuron Disease: new trials by email Literature Review of Motor Neuron Disease trials Research Report on Motor Neuron Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec Salanersen, Sham Procedure - Muscular Atrophy, Spinal | Phase 3 | Recruiting | Biogen | 42 | 2026-10-31 | 2026-10-15 |
| Efficacy and Safety of Tazbentetol in ALS Participants Tazbentetol, placebo - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Not yet recruiting | Spinogenix | 430 | 2026-10-01 | 2026-09-10 |
| An Open Label Individual Patient (OLIP)-02 Study of Nusinersen (BIIB058) Nusinersen Injectable Product - SMA - Spinal Muscular Atrophy | Phase 3 | Not yet recruiting | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 1 | 2026-09-17 | 2026-09-29 |
| A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam Salanersen - Spinal Muscular Atrophy | Phase 3 | Recruiting | Biogen | 90 | 2026-09-08 | 2026-11-13 |
| A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1) Rinzimetostat, Darolutamide, Enzalutamide - Metastatic Castration Resistant Prostate Cancer | Phase 3 | Recruiting | ORIC Pharmaceuticals | 600 | 2026-08-03 | 2026-11-03 |
| This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling Galunisertib + Nerandomilast Combination - ALS (Amyotrophic Lateral Sclerosis) | Phase 2 / Phase 3 | Not yet recruiting | Gipfel Life Sciences GmbH | 60 | 2026-06-30 | 2026-01-07 |
| A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA) Salanersen - Muscular Atrophy, Spinal | Phase 3 | Recruiting | Biogen | 30 | 2026-04-28 | 2026-10-23 |
| HEALEY ALS Platform Trial - Regimen I NUZ-001 NUZ-001, Matching placebo - Amyotrophic Lateral Sclerosis (ALS) | Phase 2 / Phase 3 | Active not recruiting | Merit E. Cudkowicz, MD | 240 | 2026-02-25 | 2026-07-20 |
| Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS Pridopidine, Placebo - Amyotrophic Lateral Sclerosis | Phase 3 | Recruiting | Prilenia | 500 | 2026-02-01 | 2026-11-17 |
| Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients Masitinib 4.5 mg/kg/day, Placebo, Riluzole (100 mg) - Amyotrophic Lateral Sclerosis (ALS) | Phase 3 | Not yet recruiting | AB Science | 412 | 2026-01-01 | 2025-10-03 |
| HD-tDCS in Amyotrophic Lateral Sclerosis: A Multicenter Randomized Controlled Trial Active HD-tDCS, Simulated HD-tDCS - Amyotrophic Lateral Sclerosis (ALS) | Phase 2 / Phase 3 | Recruiting | Universidade Federal do Rio Grande do Norte | 80 | 2025-11-28 | 2026-07-20 |
| A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) Test drug CB03-154 5mg group, Test drug CB03-154 10mg group, Test drug CB03-154 15mg group - ALS (Amyotrophic Lateral Sclerosis) | Phase 2 / Phase 3 | Recruiting | Shanghai Zhimeng Biopharma, Inc. | 240 | 2025-10-30 | 2026-09-22 |
| Real World Clinical Effectiveness & Safety of Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in Low-middle Income Countries (LMIC). vesemnogene lantuparvovec - Spinal Muscular Atrophy (SMA) | Phase 3 | Withdrawn | Lantu Biopharma | 2025-10-15 | 2026-09-25 | |
| Study of COYA 302 for the Treatment of ALS COYA 302, Placebo - Amyotrophic Lateral Sclerosis (ALS) | Phase 2 / Phase 3 | Active not recruiting | Coya Therapeutics | 120 | 2025-10-01 | 2026-10-13 |
| Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY) Debamestrocel - MSC-NTF (NurOwn), Placebo - Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis | Phase 3 | Not yet recruiting | Brainstorm-Cell Therapeutics | 200 | 2025-06-30 | 2025-05-22 |
| Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III GC101 adeno-associated virus injection - SMA - Spinal Muscular Atrophy | Phase 3 | Active not recruiting | GeneCradle Inc | 50 | 2025-05-27 | 2026-11-13 |
| Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS Acetyl-l-carnitine, Placebo - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Recruiting | Mario Negri Institute for Pharmacological Research | 246 | 2025-03-26 | 2026-10-06 |
| A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer BMS-986365, Enzalutamide, Abiraterone - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Active not recruiting | Celgene | 960 | 2025-03-13 | 2026-09-30 |
| Clinical Trial of Mexiletine Hydrochloride for Spinal and Bulbar Muscular Atrophy Mexiletine hydrochloride, Placebo - Spinal and Bulbar Muscular Atrophy | Phase 2 / Phase 3 | Active not recruiting | Masahisa Katsuno | 68 | 2025-02-28 | 2026-11-17 |
| RAPA-501 Therapy for ALS RAPA-501 Autologous T stem cells - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Recruiting | Rapa Therapeutics LLC | 41 | 2025-01-02 | 2026-09-29 |
Showing 20 of 123. Sign in to see all of them.
Amyotrophic Lateral Sclerosis (90) · Muscular Atrophy, Spinal (26) · Bulbo-Spinal Atrophy, X-Linked (8) · Muscular Atrophy (8) · Neuromuscular Diseases (6) · Spinal Muscular Atrophies of Childhood (5) · Muscular Diseases (4) · Prostatic Neoplasms (3) · Atrophy (2) · Multiple Sclerosis (2) · Neuromuscular Manifestations (2) · Sialorrhea (2) · Anorexia (1) · Breast Neoplasms (1)
Nervous System Diseases (123) · Neurodegenerative Diseases (122) · Spinal Cord Diseases (122) · Central Nervous System Diseases (121) · Neuromuscular Diseases (117) · Metabolic Diseases (90) · Nutritional and Metabolic Diseases (90) · Proteostasis Deficiencies (90) · TDP-43 Proteinopathies (90) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (15) · Genetic Diseases, Inborn (15) · Heredodegenerative Disorders, Nervous System (15) · Pathological Conditions, Signs and Symptoms (14) · Signs and Symptoms (11)
Riluzole (9) · Zolgensma (7) · Edaravone (6) · nusinersen (6) · arimoclomol (3) · enzalutamide (3) · masitinib (3) · mecobalamin (3) · pridopidine (3) · sodium phenylbutyrate and taurursodiol (3) · CK-2017357 (2) · Dexpramipexole (2) · Docetaxel (2) · Lithium Carbonate (2) · Memantine (2)
Biogen (10) · Merit E. Cudkowicz, MD (9) · Shionogi (5) · Cytokinetics (4) · Novartis Gene Therapies (4) · Novartis Pharmaceuticals (4) · AB Science (3) · Amylyx Pharmaceuticals Inc. (3) · Assistance Publique - Hôpitaux de Paris (3) · Eisai Co., Ltd. (3) · Hoffmann-La Roche (3) · Avanir Pharmaceuticals (2) · Brainstorm-Cell Therapeutics (2) · Ferrer Internacional S.A. (2) · Humanitas Mirasole SpA (2)
United States (71) · Italy (39) · France (37) · Spain (37) · United Kingdom (36) · Belgium (35) · Canada (35) · Germany (34) · Netherlands (28) · Australia (24) · Japan (24) · Sweden (22) · Ireland (18) · Poland (18) · China (11)
Merit Cudkowicz, MD (7) · Merit Cudkowicz, MD, MSc (3) · Kazunori Saeki (2) · Merit Cudkowicz (2) · Michael Benatar, MD PhD (2) · Adrian Hepner, M.D. (1) · Albert Ludolph, MD, PhD (1) · Alberto Albanese, MD (1) · Anthony J. Windebank, MD (1)
PMID 34383289, PMID 25982504, PMID 31420846, PMID 34536404, PMID 38705943, PMID 40067754, PMID 40067755, PMID 40067821, PMID 14718694, PMID 15505150, PMID 17980667, PMID 19029516, PMID 19682544, PMID 19743466, PMID 20363190, PMID 20839238, PMID 21887710, PMID 23613806, PMID 24067398, PMID 25286015, PMID 25297012, PMID 27751553, PMID 27939059, PMID 28522181, PMID 28864675, PMID 28872913, PMID 28872914, PMID 28872915, PMID 28872918, PMID 28872920, PMID 29091570, PMID 29367439, PMID 29402141, PMID 29443664, PMID 30523161, PMID 30554828, PMID 30578206, PMID 30636701, PMID 30814647, PMID 30879249, PMID 31719072, PMID 31930364, PMID 32640130, PMID 33743238, PMID 34433481, PMID 34457038, PMID 34816762, PMID 35246398, PMID 35397772, PMID 35532908
2023 (4), 2019 (3), 2025 (3), 2014 (2), 2015 (2), 2017 (2), U01NS049640 (2), 2016 (1), 2018 (1), R01NS042759 (1)